The new and enhanced VIST Enhanced Carotid and Coronary 7.7 training modules feature vital signs, complications, medication management and measurement functionality enhance to create clinical realism and elevate the educational value of simulation training. The system includes new patient cases, including chronic total occlusion and transradial access.

May 26, 2009 – AMG International GmbH last week submitted its second-generation drug-eluting stent (DES), Itrix, for regulatory review in Europe. The stent offers a bioabsorbable polymer that holds the drug.

May 26, 2009 – Biotronik Inc. recently launched its Lumax 540 series implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillator (CRT-D) devices during Heart Rhythm 2009.

May 26, 2009 – Medtronic intends to seek FDA approval for the use of cardiac resynchronization therapy (CRT) in certain mildly symptomatic heart failure patients.

While CRT is a proven life-saving therapy for some patients with advanced stages of heart failure (New York Heart Association Class III, IV), it is not currently approved for use in earlier stages, or mildly symptomatic patients.

May 26, 2009 - United Therapeutics Corp. said today the FDA approved ADCIRCA (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).

May 22, 2009 - Rafael Medical Technologies Inc. said this week it received FDA clearance for its SafeFlo Vena Cava Filter.

The clearance is for the permanent implantation of the filter in patients at risk of pulmonary embolism. CE mark was granted for the filter in 2004 for both permanent and retrieval indications.

May 22, 2009 - CPC of America Inc. filed its first patent of a synthetic sealant for the MedClose Vascular Closure System (VCS), which is an internal puncture-closing system for use in percutaneous intravascular diagnostic and interventional procedures.

May 22, 2009 - According to IMV’s recent census of cath labs in the U.S., starting in 2007 the total number of patient cases declined, with a 10 percent decline from 4.21 million in 2006 to 3.8 million in 2007, and a slight decrease of 1 percent to 3.75 million in 2008.

May 21, 2009 - Boston Scientific Corp. this week announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial.

May 22, 2009 – Biotronik said today it is partnering with Belgian biotechnology company Cardio3 BioSciences in its C-Cure stem cell clinical trial, where it will provide implantable cardioverter defibrillators (ICDs) with home monitoring.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now